BioPharma Credit


$1338.2m market cap

$0.97 last close

BioPharma Credit was incorporated in October 2016 in the UK and aims at generating predictable income for shareholders over the long term through a diversified portfolio of loans and other instruments backed by royalties or other cash flows derived from sales of approved life sciences products. This includes senior secured notes, royalty debt instruments and priority royalty tranches. BPCR may also invest in unsecured debt (up to 35% of gross assets) as well as credit-linked notes. It can also have an equity exposure of up to 15% of gross assets.

Investment summary

On 24 March 2021, BioPharma Credit (BPCR) announced that it has entered into a US$150m senior secured loan agreement alongside BioPharma Fund V (which provided a further US$150m) with LumiraDx – a next-generation, point-of-care diagnostic company. LumiraDx manufactures rapid diagnostics equipment, including antibody and antigen tests to detect SARS-CoV-2 infections, used by the UK National Health Service, the CVS Pharmacy chain in the US and widely deployed in Africa in cooperation with the Bill & Melinda Gates Foundation. The transaction assists BPCR in achieving full dividend cover this year.

Register to receive research on BioPharma Credit as it is published
Share price graph
Price performance
Actual 0.0 (1.8) 1.5
Relative* (2.2) (5.1) (16.7)
52-week high/low US$1.0/US$0.9
*% relative to local index
Key management
Alexander Perfall VP, Investor Relations & Public Affairs

Content on BioPharma Credit

You may also be interested in…